# 上海海顺新型药用包装材料股份有限公司

## Hysun (Shanghai) New Pharmaceutical Packaging Co., Ltd.

## 2022 年前三季度业绩预告

## Performance Forecast for the First Three Quarters of 2022

本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚假记载、误导性陈述或重大遗漏。

The Company and all members of the Board of Directors of the Company hereby guarantee the authenticity, accuracy and completeness of the contents of this announcement and warrant that there are no false representations, misleading statements or material omissions contained herein.

## 一、本期业绩预计情况

#### 1. Current Performance Forecast

- (一) 业绩预告期间
- (1) Period of Performance Forecast

2022年1月1日——2022年9月30日

January 1, 2022 - September 30, 2022

- (二)业绩预告情况预计净利润为正值且属于下列情形之一:
- (2) Performance ForecastThe net profit is expected to be positive and is one of the following:

□扭亏为盈 ☑同向上升 □同向下降

		上年同期
项目	2022 年 1 月-9 月	For the same
Item	January-September 2022	period of the
		previous year
归属于上市公司股东的净利润	盈利: 7,898.26 万元-8,688.09 万元	
Net profit attributable to the	Earnings: RMB78,982,600 - RMB86,880,900	7,898.26 万元
shareholders of the listed	同比上年增长: 0%-10%	RMB78,982,600
company	Year-on-year growth: 0% - 10%	
扣除非经常性损益后的净利润	盈利: 7,339.47 万元-8,112.05 万元	
和除非经常性坝缸户的伊利姆 Net profit, net of non-recurring gains and losses	Earnings: RMB73,394,700 - RMB81,120,500	7,725.76 万元
	同比上年增长: -5%-5%	RMB77,257,600
	Year-on-year growth: -5% - 5%	

其中 2022 年 7 月 1 日—2022 年 9 月 30 日预计的业绩为:

Of which the performance forecast for the period from July 1, 2022 - September 30, 2022 are as follows:

项目	2022 年 7 月-9 月	上年同期
次日 Item	July-September 2022	For the same
Item	July-September 2022	period of the

		previous year
归属于上市公司股东的净利润	盈利: 2,647.13 万元-2,850.75 万元	
Net profit attributable to the	Earnings: RMB26,471,300 - RMB28,507,500	2,036.25 万元
shareholders of the listed	同比上年增长: 30%-40%	RMB20,362,500
company	Year-on-year growth: 30%-40%	
和除北级党州县关后的海利湖	盈利: 2,470.76 万元-2,668.42 万元	
扣除非经常性损益后的净利润	Earnings: RMB24,707,600 - RMB26,684,200	1,976.61 万元
Net profit, net of non-recurring gains and losses	同比上年增长: 25%-35%	RMB19,766,100
gains and losses	Year-on-year growth: 25%-35%	

## 二、业绩预告预审计情况

#### 2. Pre-audit of Performance Forecast

本期业绩预告相关的财务数据未经会计师事务所审计。

The financial data related to the current performance forecast has not been audited by any accounting firm.

### 三、业绩变动原因说明

#### 3. Explanation on Reasons for the Changes in Performance

- 1、报告期内,公司持续推进精益管理,销售、生产、技术、质量各部门协同发力,积极开拓市场,提升效率,同时部分原材料价格有所回落。因此,预计公司 2022 年前三季度营业收入和净利润较上年同期有所增长。
- (1) During the reporting period, the Company continued to promote lean management, and the sales, production, technology, quality and all other departments made concerted efforts to actively expand the market and improve efficiency, while the prices of some raw materials dropped. Therefore, the operating revenue and net profit of the Company in the first three quarters of 2022 are estimated to increase compared to those for the same period of the previous year.
  - 2、2022年前三季度,非经常性损益对公司当期净利润的影响金额约为606.57万元。
- (2) In the first three quarters of 2022, the impact of non-recurring gains and losses on the Company's net profit for the period amounted to approximately RMB6,065,700.

### 四、其他相关说明

#### 4. Other Related Explanations

本次业绩预告由公司财务部测算,未经审计机构审计。具体财务数据将在本公司 2022 年第三季度报告中详细披露,敬请广大投资者谨慎决策,注意投资风险。

This performance forecast is prepared by the Finance Department of the Company and has not been audited by any accounting firm. Specific financial data will be disclosed in detail in the Company's Third Quarter Report of 2022. Investors are advised to make cautious decisions and pay attention to investment risks.

特此公告。

Hereby the announcement is made.

上海海顺新型药用包装材料股份有限公司 董事会 Board of Directors of Hysun (Shanghai) New Pharmaceutical Packaging Co., Ltd.

2022年10月15日 October 15, 2022